Skip to main navigation Skip to search Skip to main content

Cervical cancer incidence in Denmark: Disentangling determinants of time trend

  • Elsebeth Lynge
  • , Jeppe Bennekou Schroll
  • , Berit Andersen
  • , Kirubakaran Balasubramaniam
  • , Anna Poulsgaard Frandsen
  • , Else Helene Ibfelt
  • , Kirsten Marie Jochumsen
  • , Maja Ulrikka Bruun Laustsen
  • , Susanne Nielsen
  • , Rouzbeh Salmani
  • , Doris Schledermann
  • , Petra Birgitta Hall Viborg
  • , Marianne Waldstrøm
  • , George Napolitano
  • , Reza Serizawa
11 Citations (Scopus)

Abstract

Cervical cancer is a preventable disease. Nevertheless, stagnation has been seen in incidence rates also in countries with well-functioning healthcare. On this basis, we investigated associations between control interventions and changes in cervical cancer incidence in Denmark from 2009 to 2022. Data on human papillomavirus (HPV)-vaccination were retrieved from Staten's Serum Institute; on screening recommendations from Danish Health Authority, on screening performance from Danish Quality Database for Cervical Screening; and on cervical cancer incidence from Nordcan and Danish Cancer Register. We reported coverage with HPV vaccination (1+ dose); coverage with cervical cell samples; number of women with primary HPV tests; proportion of non-normal cell samples without timely follow-up; number of conizations; and cervical cancer incidence rates. In 2022, all women aged ≤29 had been offered childhood HPV vaccination with coverage of 80%-90%. By 2020-2022, the cervical cancer incidence rate in women aged 20-29 was 3 per 100,000; at level of disease elimination. In 2017, women aged 70+ were offered a one-time HPV screening, and by 2020-2022, the old-age peak in cervical cancer incidence had largely disappeared. From 2009 to 2022, proportion of non-normal cell samples without timely follow-up decreased from 20% to 10%, and conventional cytology was largely replaced by SurePath liquid-based cytology; these factors could explain the steady decrease in cervical cancer incidence rate. Implementation of primary HPV screening in women aged 30-59 in 2021 was reflected in a, probably temporary, increase in the 2022 cervical cancer incidence rate. In conclusion, combined interventions with childhood HPV vaccination; one-time HPV screening of elderly women; and better management of screening broke previous stagnation in cervical cancer incidence rate.

Original languageEnglish
JournalInternational Journal of Cancer
Volume155
Issue number10
Pages (from-to)1769-1779
Number of pages11
ISSN0020-7136
DOIs
Publication statusPublished - 15 Nov 2024

Keywords

  • cancer incidence rate
  • cervical cancer
  • human papillomavirus vaccination
  • screening time trend

Fingerprint

Dive into the research topics of 'Cervical cancer incidence in Denmark: Disentangling determinants of time trend'. Together they form a unique fingerprint.

Cite this